NTrans Technologies
NTrans Technologies BV is dedicated to unlocking the full potential of cell and gene therapy through innovative delivery platforms. Their mission is to become the leading non-viral delivery platform in cell and gene therapy, focusing on safe, efficient, and scalable solutions for genetic treatments. They leverage nature’s mechanisms for cellular uptake to ensure precise and secure delivery of gene-editing technologies, aiming to transform medicine and improve patient care.
Industries
Nr. of Employees
small (1-50)
NTrans Technologies
Leiden, South Holland, Netherlands
Products
GMP-ready non-viral delivery platform for ex vivo cell therapies
A proprietary, modular non-viral delivery platform designed to deliver gene-editing complexes into patient cells ex vivo, with stated attributes of high editing efficiency, cell viability preservation, intrinsic safety, simple implementation, and scalability.
NTrans Modular Delivery Platform
A game-changing, modular delivery platform designed for easy integration with therapeutic development processes for cell and gene therapies.
NTrans Technologies Platform
A proprietary, GMP-ready, non-viral delivery system that harnesses macropinocytosis for precise and secure delivery of gene-editing technologies.
GMP-ready non-viral delivery platform for ex vivo cell therapies
A proprietary, modular non-viral delivery platform designed to deliver gene-editing complexes into patient cells ex vivo, with stated attributes of high editing efficiency, cell viability preservation, intrinsic safety, simple implementation, and scalability.
NTrans Modular Delivery Platform
A game-changing, modular delivery platform designed for easy integration with therapeutic development processes for cell and gene therapies.
NTrans Technologies Platform
A proprietary, GMP-ready, non-viral delivery system that harnesses macropinocytosis for precise and secure delivery of gene-editing technologies.
Services
Collaborative development and integration of a modular non-viral delivery platform into partner therapeutic development workflows, including joint R&D and technical integration support.
Participation in funded consortia and receipt of non-dilutive grants to advance platform development and production transformation for cell and gene therapies.
Collaborative development and integration of a modular non-viral delivery platform into partner therapeutic development workflows, including joint R&D and technical integration support.
Participation in funded consortia and receipt of non-dilutive grants to advance platform development and production transformation for cell and gene therapies.
Expertise Areas
- Non-viral delivery for cell and gene therapy
- Ex vivo cell therapy development (CAR-T and TCR)
- Delivery of CRISPR-based genome editing
- Platform translation and GMP readiness
Key Technologies
- Non-viral macropinocytosis-based delivery
- Delivery of CRISPR-Cas9 RNP complexes
- Base editor delivery
- Prime editor delivery
News & Updates
EUR 10 million awarded to NecstGen, NTrans Technologies BV, Leiden University Medical Center, and Divvly to transform cell and gene therapies through the IPCEI Med4Health program.
Launch of the new branding and website for NTrans Technologies.
NTrans received non-dilutive funding from Health Holland.
NTrans joined the Dutch Life Science Conference in Leiden.
Ester Weijers, PhD, appointed as new CEO of NTrans Technologies.
NTrans awarded a feasibility study by MIT.
EUR 10 million awarded to NecstGen, NTrans Technologies BV, Leiden University Medical Center, and Divvly to transform cell and gene therapies through the IPCEI Med4Health program.
Launch of the new branding and website for NTrans Technologies.
NTrans received non-dilutive funding from Health Holland.
NTrans joined the Dutch Life Science Conference in Leiden.
Ester Weijers, PhD, appointed as new CEO of NTrans Technologies.
NTrans awarded a feasibility study by MIT.